Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma

2024/11/20 by Xavier Deschênes‐Simard, Martina Pennisi, Miguel‐Angel Perales +6 · 1 voice
Immunology and Microbiology · Medicine · #CAR-T cell therapy research #Immune Cell Function and Interaction #Lymphoma Diagnosis and Treatment

paper · doi:10.1080/10428194.2024.2430703

openalex publication_date 2024/11/20 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Abstract

To the Editor,Since the first approval of an immune checkpoint inhibitor (ICI) by the US Food and Drug Administration (FDA) in 2011, immunotherapy has emerged as a cornerstone of cancer treatment. ...

Discussions

• ! Hot off the press ! Excited to share this interesting case of long-term axi-cel persistence and to brainstorm about the role of immune checkpoint inhibitors in CAR T-cell therapies. doi.org/10.1080/ [bsky, 5 points, 0 comments]

Related

• A review of cancer immunotherapy toxicity
• Advancing CAR T-Cell Therapy
• Immunotherapy in HCC: aetiology matters
• Safe CAR-T: shedding light on CAR-related T-cell malignancies
• Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy